|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
51344813
???header.onlineuser??? :
677
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"armour a"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
|
Thongprasert S;Duffield E;Saijo N;Wu Y.-L;Chih-Hsin Yang;Chu D.-T;Liao M;Chen Y.-M;Kuo H.-P;Negoro S;Lam K.C;Armour A;Magill P;Fukuoka M.; Thongprasert S; Duffield E; Saijo N; Wu Y.-L; CHIH-HSIN YANG; Chu D.-T; Liao M; Chen Y.-M; Kuo H.-P; Negoro S; Lam K.C; Armour A; Magill P; Fukuoka M. |
| 臺大學術典藏 |
2016 |
Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial
|
Piccart-Gebhart M.; Holmes E.; Baselga J.; De Azambuja E.; Dueck A.C.; Viale G.; Zujewski J.A.; Goldhirsch A.; Armour A.; Pritchard K.I.; McCullough A.E.; Dolci S.; McFadden E.; Holmes A.P.; Tonghua L.; Im Y.-H.; CHIUN-SHENG HUANG; D?eras V.; Hillman D.W.; Wolff A.C.; Jackisch C.; Lang I.; Untch M.; Smith I.; Boyle F.; Xu B.; Gomez H.; Suter T.; Gelber R.D.; Perez E.A.; Eidtmann H.; Dinh P.; Di Cosimo S.; Harbeck N.; Tjulandin S. |
| 國立成功大學 |
2015-09 |
Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial
|
Sotiriou, C.; Venet, D.; Fumagalli, D.; Maetens, M.; Rothe, F.; Ignatiadis, M.; Bradbury, I.; Harbeck, N.; Gomez, H.; Chang, T. W.; Coccia-Portugal, M. A.; Di Cosimo, S.; De Azambuja, E.; De la Pena, L.; Nuciforo, P.; Armour, A.; Eidtmann, H.; Baselga, J.; Piccart, M.; Loi, S. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
